DIFICLIR, known generically as fidaxomicin, is an antibiotic medication specifically designed to target and treat infections caused by Clostridioides difficile, often referred to as C. difficile or C. diff. This bacterium can cause severe diarrhea and other intestinal conditions, particularly following the use of other antibiotics that disrupt the normal balance of bacteria in the gut. DIFICLIR works by inhibiting the synthesis of RNA in the bacterial cells, effectively stopping their growth and allowing the body to combat the infection. Unlike many other antibiotics, DIFICLIR is minimally absorbed into the bloodstream from the gut, focusing its action within the gastrointestinal tract to directly combat the infection while aiming to preserve the beneficial bacteria in the gut microbiome. This targeted approach helps to reduce the risk of recurrent infections, making DIFICLIR a valuable option in the treatment of C. difficile-associated diarrhea.